This morning, Chen Jining, Secretary of the Municipal Party Committee, met with Su Boke, Global Executive Director and CEO of AstraZeneca UK, and his delegation.
Chen Jining introduced the modernization construction and biopharmaceutical development in Shanghai. He said that in the final analysis, to promote Chinese path to modernization is to make people live a better life. Biopharmaceuticals is one of the three leading industries that Shanghai is focusing on developing. Since last year, multiple innovative policies have been introduced, providing strong support to enterprises in research and development facilitation, innovative drug device listing, and clinical trials, promoting new breakthroughs, and enabling the people to enjoy better medical and health benefits. AstraZeneca is a leading pharmaceutical company globally. We welcome development opportunities and will closely integrate our own advantages with Shanghai's market advantages, scientific and technological innovation advantages, clinical advantages, talent advantages, etc. on the basis of existing good cooperation. We will continue to increase investment and layout efforts, deepen innovative project cooperation and docking, and strive to provide higher quality medical and health products and services. We will make every effort to create a first-class business environment that is market-oriented, legal, and internationalized, and provide comprehensive and high-quality services for global enterprises and talent teams to cultivate and develop in Shanghai and Shenzhen.
Su Boke introduced the progress and future development plans of AstraZeneca's business in Shanghai. He said that setting the company's Asia Pacific headquarters, China headquarters, and global R&D center in Shanghai is precisely because of the importance of the Chinese market, especially Shanghai, to AstraZeneca. The purpose of leading the global senior management team to Shanghai this time is to deepen the team's understanding of China and Shanghai, strengthen their confidence in developing in China and Shanghai, continue to increase innovation investment, expand new business layout, carry out more in-depth cooperation with Chinese local innovative pharmaceutical enterprises, and contribute more to promoting high-quality development of Shanghai pharmaceutical industry and better benefiting global patients.
City leaders Li Zheng and Liu Duo attended the meeting.